Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

核医学/放射性医薬品の世界市場予測:種類別(SPECT-テクネチウム、PET-F-18)、治療薬別(ベータエミッター–I-131、アルファエミッター、近接照射療法–Y-90)、用途別(腫瘍学、心臓病学)

◆タイトル:Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024
◆商品コード:PH 3590
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年1月27日
◆ページ数:231
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は核医学/放射性医薬品の世界市場が、2019年41億ドルから2024年52憶ドルまで、年平均4.7%成長すると予測しています。本調査レポートでは、核医学/放射性医薬品の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、種類別(診断核医学、核治療薬)分析、用途別(腫瘍学、心臓病学)分析、処置別(診断処置、治療処置)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・核医学/放射性医薬品の世界市場:種類別(診断核医学、核治療薬)
・核医学/放射性医薬品の世界市場:用途別(腫瘍学、心臓病学)
・核医学/放射性医薬品の世界市場:処置別(診断処置、治療処置)
・核医学/放射性医薬品の世界市場:地域別
・競争状況
・企業概要

“The nuclear medicine market is projected to grow at a CAGR of 4.7%.”
The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period. The key factors propelling the growth of this market are the increasing incidence and prevalence of cancer & cardiovascular diseases and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices have made it difficult for a section of end users to depend on nuclear medicine. These factors are expected to hamper the growth of the nuclear medicine market during the forecast period.

“The Technetium-99m segment to hold the largest share of SPECT radiopharmaceuticals market in 2019.”
Based on type, the SPECT radiopharmaceuticals market is segmented Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to command the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80–90% of diagnostic scans and around 30 million patient examinations every year.

“In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market.”
On the basis of indication, the therapeutic nuclear medicine applications market is segmented into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market. On the other hand, the endocrine tumors segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.

“The Asia Pacific to witness the highest growth during the forecast period.”
Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019–2024. The major factors driving the growth of the Asia Pacific market include research initiatives in Japan, rising installations of PET scanners in India and China, and initiatives by the Australian government.

Break of primary participants was as mentioned below:
 By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
 By Designation: C-Level Executives: 35%, Directors: 25%, Others: 40%
 By Region: North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%
Cardinal Health (US), GE Healthcare (US), and Curium (France) were the leading players in the nuclear medicine market.

Research Coverage
This report studies the nuclear medicine market based on type, application, procedural volume assessment, and region. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the nuclear medicine market.

【レポートの目次】



★調査レポート[核医学/放射性医薬品の世界市場予測:種類別(SPECT-テクネチウム、PET-F-18)、治療薬別(ベータエミッター–I-131、アルファエミッター、近接照射療法–Y-90)、用途別(腫瘍学、心臓病学)] ( Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024 / PH 3590) 販売に関する免責事項
[核医学/放射性医薬品の世界市場予測:種類別(SPECT-テクネチウム、PET-F-18)、治療薬別(ベータエミッター–I-131、アルファエミッター、近接照射療法–Y-90)、用途別(腫瘍学、心臓病学)] ( Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024 / PH 3590) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆